Soft Tissue Sarcoma – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of soft tissue sarcoma (STS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of STS for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy for the major mature pharmaceutical markets.

Clarivate Epidemiology’s STS forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of first-line drug-treatment opportunities for STS?
  • How will improvements in survival change the number of people living with STS?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of STS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

In total, Clarivate Epidemiology forecasts 25 STS patient populations that encompass the following:

  • Diagnosed incident cases of STS by stage.
  • Diagnosed prevalent cases of STS by resection status.
  • Diagnosed recurrent cases of STS by site of recurrence.
  • Diagnosed first-line drug-treatable STS population.

Note: Coverage may vary by country.

Table of contents

  • Soft Tissue Sarcoma - Epidemiology - Emerging Markets
    • Epidemiology data
    • Methods
      • Literature review (studies included in/excluded from the analyses of STS)
      • Diagnosed incident cases
      • Stage distribution
      • Recurrent incident cases
      • Diagnosed prevalent cases
      • Drug-treatable populations
      • Risk / protective factors applied to disease forecast models
    • Reference materials
      • Bibliography
      • Glossary
      • Abbreviation table